The Bundibugyo strain of Ebola, which lacks approved vaccines or treatments, has caused 894 confirmed cases and over 200 deaths in eastern Congo, according to the Africa Centres for Disease Control and Prevention. The outbreak, centered in Ituri, has reached North and South Kivu provinces and crossed into Uganda, where 19 cases and two deaths … Read more
The U.S. Department of Agriculture (USDA) has confirmed a second case of New World screwworm in Texas, detected in a one-month-old calf in Zavala County. This follows an initial discovery earlier this month, prompting federal authorities to implement containment zones and sterile insect releases to suppress the flesh-eating parasite’s population, according to the USDA’s Animal … Read more
The Future of Lung Cancer Treatment: Is a ‘Keytruda Successor’ Finally Here? For over a decade, Merck’s Keytruda has stood as the undisputed titan of oncology. With over 44 FDA indications and annual sales exceeding $30 billion, it transformed lung cancer from a terminal diagnosis into a manageable condition for many. Now, the medical community … Read more
Eli Lilly’s Strategic Pivot: Why Vaccines Are the Next Frontier In a bold move that signals a major shift in corporate strategy, pharmaceutical giant Eli Lilly has re-entered the vaccine and infectious disease market. By acquiring three private biotech firms—Curevo, LimmaTech Biologics and Vaccine Company—in deals totaling nearly $4 billion, the company is betting that … Read more
The Deadly Intersection of Tradition and Crisis: Lessons from Congo’s Ebola Frontlines In the high-stakes environment of an infectious disease outbreak, the most dangerous obstacles are often not the virus itself, but the deep-seated cultural traditions that clash with modern medical protocols. The recent turmoil in eastern Congo, where medical facilities have become targets of … Read more
The New Era of Pharma Fraud: Beyond Simple Theft The pharmaceutical industry is currently facing a sophisticated evolution in financial crime. No longer limited to simple insurance scams, we are seeing the rise of “systemic rebate arbitrage”—where bad actors exploit the complex relationship between manufacturers, Pharmacy Benefit Managers (PBMs), and specialized health programs. A recent … Read more
The New Frontier of Bio-Security: Lessons from the Andes Virus Outbreak The recent health scare aboard the MV Hondius has served as a stark reminder that the world remains vulnerable to zoonotic spillover. While the current outbreak of the Andes virus—a specific strain of hantavirus—has been contained with limited human-to-human transmission, the event has exposed … Read more
The Death of the Annual Physical? How Wearables are Rewriting Healthcare For decades, the gold standard of preventative health has been the annual check-up: a once-a-year snapshot of your vitals, a few blood tests, and a hope that nothing went wrong in the intervening 364 days. But the landscape is shifting. We are moving from … Read more
The Ozempic Effect: What Generic GLP-1s Mean for the Future of Weight Loss and Pharma For years, the pharmaceutical world has watched the meteoric rise of semaglutide—the active ingredient in blockbuster drugs like Ozempic and Wegovy. What started as a treatment for type 2 diabetes evolved into a global cultural phenomenon, redefining how we approach … Read more
Beyond the Blockbusters: The Strategic Shift in Oncology Pipelines The pharmaceutical landscape is witnessing a pivotal shift. Even as weight-loss medications have captured global headlines, industry giants are quietly reinforcing their foundations in oncology. A prime example is Eli Lilly and Company’s recent move to acquire Ajax Therapeutics for up to $2.3 billion in cash. … Read more